Exollence Co., Ltd.
- Biotech or pharma, therapeutic R&D
Exollence is a biotech company with a proprietary EV (extracellular vesicle) platform, SWEET™, that can load any payload (siRNA, mRNA, small molecules, etc.) into EVs from any source, with GMP-ready scalability. This unique versatility overcomes industry limitations and unlocks applications from therapeutics to consumer products.
Powered by SWEET, Exollence’s pipeline includes an siRNA therapy for KRAS-mutant cancers (preclinical efficacy comparable to Lumakras®), a room-temperature stable mRNA vaccine (eliminating cold chain and LNP requirements), and an oral/nasal EV-based GLP-1 agonist therapy for obesity (a non-injectable weight-loss treatment). Exollence has also demonstrated commercial traction: its EV-based skincare products (via a partnership with COSMAX) are already generating revenue, validating the platform’s scalability and lowering investor risk through real-world manufacturing success.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}